Health Care

Pharmaceutical Industry

NERA has provided economic analysis in testimony and written reports to many of the leading international research-based and generic pharmaceutical companies. We have performed competitive analyses of proposed acquisitions involving pharmaceutical companies as well as estimated damages or costs in contract, antitrust, patent, and regulatory matters. We also have expertise in providing companies with economically sound transfer pricing methodologies and strategic planning advice. Our work has encompassed both chemical based and biotechnology products. In our pharmaceutical work, we have:

• Analyzed market definition and entry conditions in horizontal mergers involving pharmaceutical manufacturers as well as pharmaceutical wholesalers;
• Analyzed the competitive impact of pharmaceutical companies acquiring pharmaceutical benefit managers;
• Calculated damages in a wide variety of antitrust, contract dispute, and other matters;
• Assessed market definition, market share, and entry conditions in antitrust counter-claims;
• Made presentations to the federal antitrust agencies on the competitive effects of brand elimination and innovation markets;
• Advised pharmaceutical companies on the business implications of competitive trends, regulatory changes, and health care reform;
• Conducted public policy studies on intellectual property protection, parallel trade, health care reform, Medicare prescription drug proposals, and pricing investigations as they affect the pharmaceutical industry.

NERA also participates in policy discussions concerning the risks and returns of pharmaceutical research and development, and advises pharmaceutical companies on the business implications of competition, regulation, and health care reform. Our economists analyze emerging public policy issues such as the effects of regulatory delays in approving pharmaceutical products on public health and consequences of developing countries ignoring TRIPS standards on local pharmaceutical industry growth. 
 
Our experts also are experienced in the assessment of economic costs and benefits of therapeutic studies, the comparative evaluation of alternative means for controlling pharmaceutical costs by competitive and regulatory means, and assistance in evaluating reimbursement methodologies.

Please click here for more information about the firm's expertise in the pharmaceutical industry.